Targeting Mutant (V600E) B-Raf in Melanoma Interrupts Immunoediting of Leukocyte Functions and Melanoma Extravasation

Shile Liang,1 Arati Sharma,3 Hsin-Hsin Peng,2 Gavin Robertson,3,4,5,6,7 and Cheng Dong1,2,7

1Huck Institutes of the Life Sciences and 2Department of Bioengineering, The Pennsylvania State University, University Park, Pennsylvania; Departments of Pharmacology, Pathology, and Dermatology, The Pennsylvania State University College of Medicine; 3The Foreman Foundation for Melanoma Research; and 4The Penn State Melanoma Therapeutics Program, Hershey, Pennsylvania

Abstract

Polymorphonuclear neutrophils (PMN) facilitate melanoma cell extravasation under dynamic flow conditions by the binding of intercellular adhesion molecule-1 (ICAM-1) on melanoma cells to β2 integrins on PMNs, which is mediated by endogenously produced chemokine interleukin 8 (IL-8) from the tumor microenvironment. However, little is known about the role of B-Raf, the most mutated gene in malignant melanomas, in this process. In this study, we investigated the functional importance of B-Raf in melanoma extravasation by using short interfering RNA to reduce expression/activity of mutant V600E B-Raf in melanoma. Results indicated that knockdown of mutant V600E B-Raf inhibited melanoma cell extravasation in vitro and subsequent lung metastasis development in vivo. Mechanistic studies showed that inhibition of V600E B-Raf significantly reduced the constitutive secretion of IL-8 from melanoma cells as well as the capacity of endogenous IL-8 production from the melanoma-PMN microenvironment. Furthermore, a reduction in ICAM-1 expression on melanoma cells was detected following mutant V600E B-Raf knockdown. Together, these results suggest that targeting mutant V600E B-Raf reduces melanoma cell extravasation by decreasing IL-8 production and interrupting ICAM-1-β2 integrin binding of melanoma cells to the endothelium mediated by PMNs in the microcirculation, which provides a rationale and mechanistic basis for targeting mutant V600E B-Raf to inhibit melanoma extravasation and subsequent metastasis development. [Cancer Res 2007;67(12):5814–20]

Introduction

Melanoma is a skin cancer characterized by abnormal proliferation of melanocytes that invade the basement membrane. Once melanoma metastasizes, it is notoriously resistant to diverse chemotherapeutic agents, and for many patients, prognosis is poor. Consequently, the search for novel antimelanoma agents continues. Studies have shown that mutation in B-Raf, a glutamic acid for valine substitution at codon 600 (V600E) in exon 15, happens in ~60% of melanomas (1–4). B-Raf encodes a RAS-regulated kinase that mediates cell growth and malignant transformation (5). B-Raf mutation is implicated in constitutive activation and hyperactivation of downstream proteins in the signaling cascade that promotes melanoma adhesion, migration, and proliferation (1, 4, 6, 7).

Melanoma metastasis requires that tumor cells detach from a primary site and invade the surrounding stroma, survive immune defenses and turbulence of the blood circulation after invading into the circulatory system, extravasate through the endothelial lining of blood vessels, and finally form a new colony in the surrounding tissue. Human polymorphonuclear neutrophils (PMN), which compose 50% to 70% of circulating leukocytes, have been shown under certain circumstances to promote tumor adhesion and transendothelial extravasation (8, 9). Miele et al. (10) reported that a dose- and time-dependent increase in surface expression of intercellular adhesion molecule-1 (ICAM-1) was found in human malignant melanoma cells. Furthermore, binding between ICAM-1 on malignant melanoma cells and β2 integrins (e.g., CD11a/CD18, LFA-1 and CD11b/CD18, Mac-1) found on PMNs mediates melanoma extravasation through the endothelium (Fig. 1; refs. 11, 12). Endogenous interleukin 8 (IL-8) secreted by melanoma cells increases β2 integrin expression on PMNs and modulates PMN-facilitated melanoma extravasation (12). IL-8 protein production requires the activation of nuclear transcription factor NFKB, NF-IL-6 (C/EBP), or activator protein-1 (13, 14). However, little is known about the regulation of IL-8 production and of interactions between PMN and melanoma by mutant V600E B-Raf in melanoma cells, which may, in turn, influence melanoma extravasation.

In the present study, we evaluated the role played by mutant V600E B-Raf in melanoma extravasation and metastasis development. Short interfering RNA (siRNA) targeting mutant V600E B-Raf was used to reduce expression and/or activity of mutant V600E B-Raf in melanoma cells. Results suggest that inhibition of mutant V600E B-Raf reduced melanoma metastasis in vivo by decreasing melanoma cell extravasation. The mechanism for reduced melanoma extravasation was due to decreased ICAM-1 expression, which occurred with decreased mutant V600E B-Raf expression levels. In addition, constitutive secretion of the chemokine IL-8 from melanoma cells, as well as the capacity of increased IL-8 production from a melanoma-PMN microenvironment, was significantly decreased following inhibition of mutant V600E B-Raf. Coupling these observations with previous studies showing that endogenously produced IL-8 and ICAM-1-β2 integrin binding mediate melanoma extravasation (11, 12) provides a rationale and mechanistic basis for targeting mutant V600E B-Raf to inhibit melanoma extravasation and subsequent metastasis development.

Materials and Methods

Cell preparations. The human melanoma cell lines 1205 Lu and UACC 903M containing high levels of mutant V600E B-Raf (15, 16) were grown in DMEM (Invitrogen) supplemented with 10% fetal bovine serum (FBS; Invitrogen). Green fluorescent protein (GFP)-tagged versions of 1205 Lu...
Colocalization of mouse PMN and human melanoma cell line. Colocalization of mouse PMNs and human melanoma cells in lungs was used to verify interactions between cells and provide evidence of tethering of melanoma cells to the endothelium lining mediated by PMNs. Briefly, $1 \times 10^5$ GFP-tagged human metastatic melanoma cells (1205 Lu) in 0.2 mL of HBSS were injected i.v. into the lateral tail veins of nude mice. After 24 h, phycoerythrin-conjugated rat anti-mouse Gr-1 monoclonal antibody (BD Pharmingen) at a concentration of 1 mg/kg of body weight in 100-μL PBS was injected i.v. into the lateral tail veins of mice. Mice were sacrificed 2 h later and lungs analyzed using a Nikon SMZ 1500 dissecting microscope with fluorescence detection capabilities.

ELISA determination. At the end of coculture assays, cell-free supernatants were collected by centrifugation at $430 \times g$ for 5 min and IL-8 was quantified by a sandwich ELISA following standard protocols. Primary and secondary antibody pairs were obtained from R&D Systems. Standard human recombinant IL-8 was also obtained from R&D Systems and a standard curve was included in each ELISA plate. Plates were read on a Packard Spectraccoat at 405 nm and the data analyzed using I-Smart Software. Intra-assay variation was typically 10% to 15%.

Flow migration assay. Flow migration assay was measured in a modified 48-well chemotactic Boyden chamber consisting of a top and bottom plate separated by a gasket (8, 20). Before each experiment, a monolayer of E-selectin was grown (typically 36 h after cell seeding) on sterile polivinylpyrrolidone-free polycarbonate filters (8 μm pore size; NeuroProbe) precoated with fibronectin (30 μg/mL; 3 h; Sigma). The center wells of bottom plates were filled with soluble chemotactic agent IV collagen [100 μg/mL in RPMI 1640/0.1% bovine serum albumin (BSA); BD Biosciences] and surrounding control wells were filled with medium (RPMI 1640/0.1% BSA). Studies have shown that melanoma cells express αvβ3 integrin receptors for soluble collagen IV protein and migrate toward collagen IV stimulation (21, 22). Apparatus was assembled by placing filter on bottom plate followed by addition of a sealing gasket and top plate. The chamber was primed with 37°C medium to eliminate bubbles in the system. For migration assay, 5 $\times 10^5$ melanoma cells only or PMNs together with melanoma cells (5 $\times 10^5$ of each) were put in the chamber either under static conditions or under shear flow conditions for 4 h in a 37°C, 5% CO2 incubator. To quantify migration, migrated cells were stained with Protocol Brand Hema3 solution (Fisher Scientific) and counted using an inverted microscope (Diaphot 330, Nikon) with NIH Image software (v. 1.64.02).

Electromobility shift assay. Nuclear extracts were prepared by lysing 106 cells in 0.1% NP40 in buffer A [10 mmol/L HEPES (pH 7.9), 10 mmol/L KCl, 0.1 mmol/L EDTA, 0.1 mmol/L EGTA, 1 mmol/L DTT, 0.5 mmol/L phenylmethylsulfonyl fluoride (PMSF)] for 15 min. Cells were then spun to separate nuclei from cytoplasmic component. Nuclear pellet was resuspended in buffer C [20 mmol/L HEPES (pH 7.9), 0.4 mol/L NaCl, 1 mmol/L EDTA, 1 mmol/L EGTA, 1 mmol/L DTT, 1 mmol/L PMSF] for 15 min. Annealed NF-κB binding site oligonucleotides (5’-AGCTTATAGCTTCCGTATCTTCAAC-3’ and 5’-AGGCTTCTGGAAGTCCCGCCTTGCG-3’) were end-filled with [α-32P]dCTP using bacterial Klenow fragment (Promega). The DNA probe was incubated with nuclear extracts in a reaction mixture containing dl-Dc (GE Healthcare), 0.25 mol/L HEPES (pH 7.5), 0.6 mol/L KCl, 9% glycerol, 1 mmol/L EDTA, 0.75 mol/L DTT, and 50 mmol/L MgCl2 for 30 min at room temperature. A total of 0.5 μg of anti-p50 or anti-p65 (NF-κB, Santa Cruz Biotechnology) was added to the reaction mixture during the 30-min incubation to supershift complexes. The incubation mixtures were run on a 6% polyacrylamide gel at 130 V and the gel was dried and photographed.

Statistics. All results were shown as mean ± SE unless otherwise stated. Student’s t test was used for pairwise comparisons and ANOVA was used for groupwise comparisons, followed by the appropriate post hoc test (Dunnett’s, Tukey’s, or Dunn’s). Results were considered significant at $P < 0.05$.

Results

SiRNA-mediated inhibition of mutant V600E B-Raf reduced melanoma metastases. Because B-Raf is the most mutated gene and UACC 903M were used for metastasis assays. Ei cells were fibroblast-like cells transfected to express human E-selectin and ICAM-1 (providing by Dr. Scott Simon, University of California Davis, Davis, CA) and were maintained in culture as previously described (17). Use of PMNs was approved by the Pennsylvania State University Institutional Review Board (#19311). Fresh human blood was collected from healthy adults by venipuncture. PMNs were isolated using a Histopaq (Sigma) density gradient as described by the manufacturer and kept at 4°C in Dulbecco’s PBS containing 0.1% human serum albumin until use. Cell preparations were 99.5% pure PMNs, confirmed by a Diff-Quik stain (Dade Behring, Inc.). In the cases of PMN and melanoma cell coculture, PMNs resuspended in RPMI 1640 supplemented with 5% FBS were added onto the confluent melanoma cell lines (1:1 ratio) directly and cocultured for 4 h. Ninety-five percent melanoma cells stay alive after 4-h contact culture with PMNs (data not shown).

In vitro and in vivo siRNA studies. SiRNA (100 pmol) was introduced into 1 $\times 10^6$ 1205 Lu or UACC 903M via nucleofection with an Amaxa Nucleofector using Solution R/program K-17 as previously described (15). The resultant transfection efficiency following nucleofection was >95% (15) and knockdown of mutant V600E B-Raf protein in 1205Lu and UACC 903M melanoma cells persisted beyond 8 days in culture compared with control cells nucleofected with scrambled siRNA (18). Specificity of using this siRNA approach to knock down mutant V600E-B-Raf has previously been described (18, 19). Duplexed stealth siRNA (Invitrogen) was used for these studies. The sequence for each respective siRNA is as follows: scrambled siRNA, AAUUCUCCGACUGUCAGUAGA; MUT B-Raf, GGUCUAGCUACGACGA- GAAACUCGUAG; scrambled siRNA for ICAM-1, GCTTGAGCAGTATGAGATA; ICAM-1, GCTGAGTGGCAGTAAATA.

Animal experimentation was done according to protocols approved by the Institutional Animal Care and Use Committee at The Pennsylvania State University College of Medicine. SiRNA (100 pmol) was nucleofected into GFP-tagged 1205 Lu or UACC 903M cells, which were then replated in culture dishes. Thirty-six hours later, 1 $\times 10^6$ of 1205 Lu or 0.5 $\times 10^5$ of UACC 903M in 0.2 mL of HBSS were injected i.v. into the lateral tail veins of nude mice. The effect of siRNA knockdown in melanoma xenograft module can last up to day 17.5 (19). Mice were sacrificed 17 days later and lungs were analyzed for the presence of fluorescent tumors using a Nikon SMZ 1500 dissecting microscope with a Plan Apo 1.6× objective and fluorescence detection capabilities. Images of five random fields were photographed at a magnification of ×4.8 from the ventral surface of each lung and the number of fluorescent tumors as well as area scored in pixels occupied by each tumor was quantified using IP lab imaging software (Scanalytics). Duplicate experiments consisting of eight animals were used per group.
in melanos, it is an attractive therapeutic target to inhibit melanoma metastasis. To develop a more thorough understanding of its function in metastasis, siRNA was used to knockdown expression of mutant \( V_{600EB-Raf} \) in the metastatic human melanoma cell lines 1205 Lu and UACC 903M. Experimental metastasis development was studied by nucleofecting siRNA into melanoma cells, allowing recovery in culture for 1.5 days followed by i.v. injection of cells into the tail veins of nude mice. Seventeen days later, mice were euthanized and number and size of lung metastases scored. Figure 2A shows that reducing expression/activity of mutant \( V_{600EB-Raf} \) significantly decreased the metastatic potential of 1205 Lu and UACC 903M cells. A significant 5- to 7-fold decrease in tumors >1,500 pixels was found following inhibition of \( V_{600EB-Raf} \) versus control animals injected with cells nucleofected with scrambled siRNA (Fig. 2A, left). Similar results were observed in UACC 903M cells following inhibition of \( V_{600EB-Raf} \), with a 2- to 3-fold decrease in metastases >1,500 pixels compared with a scramble siRNA control (Fig. 2A, right).

Previous studies have shown that human PMN facilitates melanoma extravasation in vitro (11, 12). To investigate the interaction of melanoma cells with mouse PMNs, colocalization of green GFP-tagged melanoma cells and red phycoerythrin-tagged mouse PMNs in the lungs was studied. Results showed that green GFP-tagged 1205 Lu cells and red phycoerythrin-labeled PMNs could be detected microscopically in the lung stroma (Fig. 2B). More importantly, ~13% melanoma cells and mouse PMNs were colocalized together, indicating that mouse PMNs are also facilitating melanoma cell adhesion to the endothelium, which could promote extravasation and thus metastases.

**Inhibiting mutant \( V_{600EB-Raf} \) reduced melanoma cell extravasation.** Melanoma cell lung metastasis in vivo requires adhesion to and subsequent extravasation through the endothelial lining of lung vessels (23). To evaluate the role of mutant \( V_{600EB-Raf} \) in facilitating melanoma extravasation, 1205 Lu cell extravasation was tested using an *in vitro* flow migration model (Fig. 3). Under static condition, melanoma only (without PMNs) migration was reduced by 25% following mutant \( V_{600EB-Raf} \) inhibition (Fig. 3A). Under flow conditions of 4 dyn/cm² when PMNs were not present, very few migrations of melanoma cells were observed and there were no migratory differences between control cells and those in which mutant \( V_{600EB-Raf} \) had been inhibited (Fig. 3B, −Neutrophil). Previous studies have shown that PMNs facilitated melanoma adhesion and subsequent extravasation through an endothelial-like cell monolayer (8, 11, 12, 20). Our results confirmed that PMNs promoted 1205 Lu melanoma cell migration under flow conditions of 4 dyn/cm² (Fig. 3B, +Neutrophil) compared with melanoma cells alone (Fig. 3B, −Neutrophil). Furthermore, inhibition of mutant \( V_{600EB-Raf} \) significantly retarded PMN-mediated melanoma cell extravasation by ~2-fold under flow conditions (Fig. 3B, +Neutrophil), indicating that inhibition of mutant \( V_{600EB-Raf} \) may affect interactions between PMNs and melanoma cells. These data showed that inhibition of mutant \( V_{600EB-Raf} \) significantly retards melanoma extravasation across the endothelial-like cell monolayer, suggesting one potential mechanism for regulating metastasis development.

**Inhibiting mutant \( V_{600EB-Raf} \) reduced IL-8 production from a melanoma-PMN microenvironment.** Prior studies report that endogenously produced IL-8 mediates PMN-facilitated melanoma extravasation (12, 24). To evaluate the role played by mutant \( V_{600EB-Raf} \) in chemokine production from melanoma cells, which could affect melanoma cell extravasation, cells nucleofected with siRNA against mutant \( V_{600EB-Raf} \) were examined for IL-8 production. Results showed that inhibition of mutant \( V_{600EB-Raf} \) significantly reduced IL-8 production from melanoma cells alone. Specifically, IL-8 produced by control melanoma cells (untransfected melanoma and melanoma nucleofected with buffer only or scrambled siRNA) was ~300 pg/mL/10⁵ cells (Fig. 4A). However, inhibition of mutant \( V_{600EB-Raf} \) resulted in ~2-fold less IL-8 production (Fig. 4A). In addition, IL-8 production from the melanoma-PMN microenvironment was also inhibited after knockdown of mutant \( V_{600EB-Raf} \). Results showed that, following coculture of PMN and control melanoma cells, IL-8 production increased ~1.5-fold compared with the summed background levels of melanoma and PMN cultured alone (Fig. 4B). In contrast, approximately equivalent or slightly reduced levels of IL-8 were detected in the cocultures between PMN and melanoma.
cells (1205 Lu or UACC 903M) nucleofected with siRNA targeting mutant \( V_{600}E-B-Raf \) (Fig. 4B). These data suggest that knockdown of mutant \( V_{600}E-B-Raf \) significantly reduced IL-8 production from melanoma cells alone and reduced the capacity of IL-8 production from the tumor microenvironment involving the immune system.

Disruption of ICAM-1-\( \beta_2 \) integrin binding between melanoma and PMN following inhibition of mutant \( V_{600}E-B-Raf \) retarded melanoma extravasation. Previous studies have shown that functional binding of ICAM-1 expressed on melanoma to \( \beta_2 \) integrin (LFA-1 and Mac-1) ligands expressed on PMNs caused cooperative tethering of PMN-melanoma aggregate to endothelium, which subsequently promotes melanoma extravasation (8, 12, 24). To investigate the functional role of ICAM-1 on melanoma to facilitate melanoma extravasation, melanoma cells were nucleofected with siRNA to reduce ICAM-1 expression, and extravasation under flow conditions was then measured. Flow cytometry showed that siRNA-mediated knockdown of ICAM-1 resulted in reduced expression of ICAM-1 (Fig. 5A). Flow migration results indicated that siRNA-mediated knockdown of ICAM-1 reduced melanoma cell extravasation significantly compared with the controls (Fig. 5B). These results suggested an important role for ICAM-1 in melanoma extravasation under flow conditions. Interestingly, inhibition of mutant \( V_{600}E-B-Raf \) reduced expression of ICAM-1 on melanoma cells to a similar level of that observed following siRNA ICAM-1 knockdown (Fig. 5A). In addition, extravasation of melanoma cells was reduced even more significantly following inhibition of mutant \( V_{600}E-B-Raf \) (Fig. 5B) compared with siRNA ICAM-1 knockdown cases, suggesting that inhibition of mutant \( V_{600}E-B-Raf \) has multiple effects other than reducing ICAM-1 expression.

Our results above have shown that inhibition of mutant \( V_{600}E-B-Raf \) retarded IL-8 production in melanoma-PMN microenvironment. IL-8 has been shown to activate Mac-1 expression on PMNs (25, 26); we then investigated the effects of inhibiting mutant \( V_{600}E-B-Raf \) on the expression of Mac-1 on PMNs. Results showed that Mac-1 expression on PMNs increased ~2-fold following coculture with control melanoma cells (Fig. 5C). In contrast, in the cases of PMN cocultured with 1205 Lu cells following inhibition of mutant \( V_{600}E-B-Raf \), Mac-1 expression on PMNs was unchanged and significantly less than controls (Fig. 5C).

Collectively, these data indicated that knockdown of mutant \( V_{600}E-B-Raf \) inhibited ICAM-1 expression on the surface of melanoma cells as well as Mac-1 up-regulation on PMNs after PMN-melanoma coculture, which in turn retarded PMN-facilitated melanoma extravasation through disruption of ICAM-1-\( \beta_2 \) integrin binding.

Disruption of NF-\( \kappa \)-B activity following inhibition of mutant \( V_{600}E-B-Raf \) reduced IL-8 levels and ICAM-1 expression. IL-8 protein production requires the activation of nuclear NF-\( \kappa \)-B (13, 14). NF-\( \kappa \)-B has also been reported to induce ICAM-1 expression on melanoma cells (27). Previous studies have implicated Raf kinases in NF-\( \kappa \)-B signaling (14, 28). To investigate whether inhibition of mutant \( V_{600}E-B-Raf \) disrupts NF-\( \kappa \)-B signaling, thereby reducing IL-8 production from melanoma cells and ICAM-1 expression on melanoma cells, electromobility shift assay was used to measure NF-\( \kappa \)-B expression in 1205 Lu. Results indicate that NF-\( \kappa \)-B expression was reduced by ~50 % following inhibition of mutant \( V_{600}E-B-Raf \) (Fig. 6A). To further evaluate the role played by NF-\( \kappa \)-B in IL-8 production, 1205 Lu were pretreated with pyrrolidinedithiocarbamate (100 \( \mu \)mol/L; Calbiochem), a NF-\( \kappa \)-B inhibitor, for 1 h and IL-8 production was measured by ELISA. Results showed that IL-8 levels decreased significantly compared with untreated control (Fig. 6B). In addition, ICAM-1 expression on melanoma cells after pyrrolidinedithiocarbamate treatment was also reduced compared with untreated control (Fig. 6B). Together, these results suggest that interruption of downstream NF-\( \kappa \)-B signaling following inhibition of mutant \( V_{600}E-B-Raf \) reduced IL-8 production and ICAM-1 expression from melanoma cells to decrease melanoma extravasation.

Discussion

In this study, a unique strategy using transient siRNA-mediated knockdown of mutant \( V_{600}E-B-Raf \) has been used to show that development of metastatic lung tumors was significantly reduced due to the disruption of extravasation through endothelium by targeted inhibition of mutant \( V_{600}E-B-Raf \). As a result of the
inhibition of mutant V600E-B-Raf, the interactions between ICAM-1 on melanoma and \( \beta_2 \) integrins on PMN as well as the endogenously IL-8 production were disrupted, which in turn reduced melanoma extravasation. This is the first study to identify the role of mutant V600E-B-Raf in PMN-facilitated melanoma extravasation, suggesting a potential mechanism for preventing the metastatic process.

The extravasation of melanoma cells was significantly reduced under static conditions following inhibition of mutant V600E-B-Raf. A previous study has shown that melanoma cell migration to type IV collagen under static condition requires activation of NF-\( \kappa \)B (29). We now show that NF-\( \kappa \)B activation in melanoma cells is reduced after inhibition of mutant V600E-B-Raf, indicating a potential mechanism for reduced extravasation under static conditions. This observation is supported by previous studies showing that mutant V600E-B-Raf renders the mitogen-activated protein pathway constitutively active, thereby eliciting constant activation of downstream signaling components and the corresponding transcription factor substrates including NF-\( \kappa \)B (30, 31). Cancer Research happens when extravasated cells proliferate and form secondary tumors (32). Our in vitro proliferation experiments showed reduced growth of melanoma cells after knockdown of

---

**Figure 4.** Inhibiting V600E-B-Raf reduced IL-8 production. A, inhibition of mutant V600E-B-Raf significantly reduced IL-8 production from melanoma cells (1205 Lu and UACC 903M) cultured alone compared with the control melanoma cells (untransfected melanoma and melanoma nucleofected with buffer only or scrambled siRNA). Columns, mean; bars, SE. B, IL-8 production from tumor microenvironment (including both PMN and melanoma cells) increased after PMN coculture with control melanoma cells (~1.5-fold), whereas IL-8 production either remained the same or was even reduced after PMN coculture with melanoma cells treated with siRNA against mutant V600E-B-Raf. Values were normalized to the summed background level of PMN and melanoma cells cultured alone. Columns, mean; bars, SE.

---

**Figure 5.** Disruption of ICAM-1/\( \beta_2 \) integrin binding mechanism in PMN-mediated melanoma extravasation in vitro after knockdown of mutant V600E-B-Raf. A, ICAM-1 expression on melanoma cells (1205 Lu and UACC 903M) was reduced after knockdown of mutant V600E-B-Raf and ICAM-1 using siRNA. B, knockdown of mutant V600E-B-Raf and ICAM-1 inhibited PMN-mediated melanoma extravasation. Columns, mean; bars, SE. C, Mac-1 expression on PMN after coculture with melanoma cells (1205 Lu and UACC 903M). Mac-1 expression on PMN increased significantly after PMN coculture with control melanoma cells (untransfected melanoma and melanoma nucleofected with buffer only or scrambled siRNA). However, the coculture between PMN and melanoma cells treated with siRNA against V600E-B-Raf did not significantly increase Mac-1 expression on PMN. Values were normalized to background Mac-1 expression on PMN alone. Columns, mean; bars, SE.
inhibition of mutant V600EB-Raf (data not shown). Therefore, besides the interruption of extravasation after inhibition of mutant V600EB-Raf, the decreased proliferation of extravasated cells may also contribute to inhibition of metastasis.

Chemokines or cytokines secreted by tumor cells and/or PMN play important roles in communication between melanomas and PMN. Therefore, disruption of the signals between these cell types could be used for therapeutic advantages (33). IL-8 expression in PMN. Therefore, disruption of the signals between these cell types could be used for therapeutic advantages (33). IL-8 expression in these anoxic tumor areas is dependent on NF-κB activity after inhibition of mutant V600EB-Raf in melanoma cells alone. It is possible to attribute this observation to the disruption of NF-κB signaling after inhibition of mutant V600EB-Raf. In support of this possibility, mutant forms of B-Raf have been reported to be able to activate NF-κB signaling (30). Furthermore, our results indicate that disruption of ICAM-1 expression on melanoma cells is due to the disruption of downstream NF-κB signaling that causes reduced endogenous IL-8 production and the disruption of ICAM-1/β2 integrin binding that is essential for PMN-facilitated melanoma extravasation. Therefore, this study suggests that targeting mutant V600EB-Raf signaling may offer a potential mechanism for therapeutic inhibition of NF-κB function in melanoma.

Acknowledgments

Received 11/16/2006; revised 3/21/2007; accepted 4/13/2007.

Grant support: NIH grants CA-97200 (C. Dong) and MO1RR-10732 (GCRC), National Science Foundation grant BES-0138474 (C. Dong), Johnson & Johnson Innovative Technology Research Seed Grant Program (C. Dong and G.P. Robertson), Grace Woodward Grants in Engineering and Medicine (C. Dong and G.P. Robertson), The American Cancer Society grant RSG-04-053-01-GMC (G.P. Robertson), and The Melanoma Research Foundation and The Foreman Foundation for Melanoma Research (G.P. Robertson).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
References


Downloaded from cancerres.aacrjournals.org on July 21, 2017. © 2007 American Association for Cancer Research.
Targeting Mutant (V600E) $B-Raf$ in Melanoma Interrupts Immunoediting of Leukocyte Functions and Melanoma Extravasation

Shile Liang, Arati Sharma, Hsin-Hsin Peng, et al.


<table>
<thead>
<tr>
<th>Updated version</th>
<th>Access the most recent version of this article at:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><a href="http://cancerres.aacrjournals.org/content/67/12/5814">http://cancerres.aacrjournals.org/content/67/12/5814</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Cited articles</th>
<th>This article cites 37 articles, 17 of which you can access for free at:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><a href="http://cancerres.aacrjournals.org/content/67/12/5814.full#ref-list-1">http://cancerres.aacrjournals.org/content/67/12/5814.full#ref-list-1</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Citing articles</th>
<th>This article has been cited by 15 HighWire-hosted articles. Access the articles at:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><a href="http://cancerres.aacrjournals.org/content/67/12/5814.full#related-urls">http://cancerres.aacrjournals.org/content/67/12/5814.full#related-urls</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>E-mail alerts</th>
<th>Sign up to receive free email-alerts related to this article or journal.</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Reprints and Subscriptions</th>
<th>To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at <a href="mailto:pubs@aacr.org">pubs@aacr.org</a>.</th>
</tr>
</thead>
</table>

| Permissions | To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org. |